Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5).
Renchi YangShujie WangXuefeng WangJing SunAmpaiwan ChuansumritJianfeng ZhouChristophe SchmittWanling HsuJeffrey XuLindong LiTiffany ChangXielan ZhaoPublished in: Research and practice in thrombosis and haemostasis (2022)
Emicizumab 1.5 mg/kg once weekly and 6 mg/kg every 4 weeks demonstrated bleed control in this study population, was well tolerated, and could improve use of prophylaxis in people with hemophilia A.
Keyphrases